However, most of these studies come from years when IgG ACPA was not yet known as the best predictive autoantibody for treatment outcomes in RA and, therefore, information on IgG ACPA in these studies is lacking [11, 28–32]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.